RALINEPAG

Ralinepag is a selective prostacyclin receptor (IP) agonist that promotes vasodilation and reduces pulmonary vascular resistance. It is in development for pulmonary arterial hypertension. Side effects include headache, flushing, nausea, diarrhea, jaw pain, and hypotension.

SKU: 9f92956a56fb Category: Tag:

Product Description


Mechanism of Action

RALINEPAG (ID 27328) demonstrates an exceptionally broad biochemical influence profile integrating multi‑axis signalling interference, deep enzymatic cascade modulation, mitochondrial‑network reprogramming, ion‑flux recalibration, structural‑protein remodelling, and transcription‑factor pathway redistribution. Its conformational flexibility enables high‑affinity docking to catalytic residues, regulatory allosteric sites, transmembrane helices, scaffolding complexes, and cytoskeletal polymers. This results in cross‑system modulation spanning metabolic, structural, genomic and stress‑adaptive biological layers.

Mechanistically, the compound can perturb phosphorylation landscapes, alter propagation velocity across MAPK, JNK, ERK, p38 and PI3K–AKT pathways, shift G‑protein signalling bias, redistribute intracellular Ca²⁺ waveforms, modulate cAMP–PKA activity, and influence mitochondrial ROS leakage thresholds. Secondary messenger amplification, membrane‑potential polarity adjustments and ATP/ADP cycle reshaping are frequently observed across experimental substrates.

Advanced Research Applications

RALINEPAG is applied in high‑precision laboratory environments for:

  • Deep kinome‑mapping and cross‑cascade interference modelling
  • Receptor–ligand structural docking with meta‑stability prediction
  • Organelle‑stress analysis including UPR, ER stress, mitochondrial oxidative load and mitophagy balance
  • Multi‑omics transcriptome reconstruction with clustering of regulatory subnetworks
  • High‑resolution cytoskeletal dynamics mapping (actin tension, tubulin flux, scaffold integrity)
  • Cell‑fate modelling across apoptosis, necroptosis, ferroptosis and autophagic flux states
  • AI‑driven SAR/QSAR modelling for compound performance optimisation

Toxicodynamics & Hazard Spectrum

At elevated or prolonged exposure, expected risks include:

  • Acute ROS escalation with collapse of antioxidant buffering systems
  • Mitochondrial fragmentation or electron‑transport chain impairment
  • Severe Ca²⁺/Na⁺/K⁺ ion‑channel dysregulation
  • Cytoskeletal depolymerisation causing mechanical instability
  • Membrane rupture or lipid‑bilayer thinning
  • Hyperactivation of inflammatory signalling (NF‑κB, STAT families, IRF genes)
  • Activation of programmed‑cell‑death pathways on multiple axes
  • Epigenetic perturbation including methylation drift and histone‑mark imbalance

For expert laboratory use only — not for any form of biological exposure.

Datasheet


Molecular Formula

C23H26ClNO5

Molecular Weight

431.9 g/mol

CAS Number

1187856-49-0

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Ralinepag; 1187856-49-0; APD-811; APD811; 2-((trans-4-((((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetic acid

IUPAC/Chemical Name

2-[[4-[[(4-chlorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid

InChl Key

NPDKXVKJRHPDQT-UHFFFAOYSA-N

InChl Code

InChI=1S/C23H26ClNO5/c24-19-10-12-21(13-11-19)25(20-4-2-1-3-5-20)23(28)30-15-18-8-6-17(7-9-18)14-29-16-22(26)27/h1-5,10-13,17-18H,6-9,14-16H2,(H,26,27)

References

https://pubchem.ncbi.nlm.nih.gov/compound/44219292;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download